Your browser doesn't support javascript.
loading
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
Geva, Ravit; Voskoboynik, Mark; Dobrenkov, Konstantin; Mayawala, Kapil; Gwo, Jennifer; Wnek, Richard; Chartash, Elliot; Long, Georgina V.
Affiliation
  • Geva R; Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.
  • Voskoboynik M; Nucleus Network, Alfred Hospital, Monash University, Melbourne, Victoria, Australia.
  • Dobrenkov K; Merck & Co, Inc, Kenilworth, New Jersey.
  • Mayawala K; Merck & Co, Inc, Kenilworth, New Jersey.
  • Gwo J; Merck & Co, Inc, Kenilworth, New Jersey.
  • Wnek R; Merck & Co, Inc, Kenilworth, New Jersey.
  • Chartash E; Merck & Co, Inc, Kenilworth, New Jersey.
  • Long GV; Royal North Shore Hospital, St. Leonards, New South Wales, Australia.
Cancer ; 126(22): 4926-4935, 2020 11 15.
Article in En | MEDLINE | ID: mdl-32809217
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptors, Tumor Necrosis Factor / Combined Modality Therapy / Antibodies, Monoclonal, Humanized / Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Male / Middle aged Language: En Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptors, Tumor Necrosis Factor / Combined Modality Therapy / Antibodies, Monoclonal, Humanized / Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans / Male / Middle aged Language: En Year: 2020 Type: Article